Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Last trade$106.20
Day change-$0.91 (-0.85%)
Day range$105.93 – $107.83
Volume1,727,564
Market cap$61.59B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$61.59B
Price / earnings
60.3×
Price / book
5.67×
Price / sales
9.23×
EV / sales
8.85×
EV / EBITDA
28.42×
Profitability
Earnings per share
$1.78
Return on assets
7.22%
Return on equity
9.4%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.06×
Current ratio
4.6×
Quick ratio
3.86×
Cash ratio
1.97×
Cash flow
Price / cash flow
35.87×
Price / free cash flow
43.25×
Free cash flow
$1.42B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EW, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.72B
$1.74B
$1.65B
$1.57B
$1.55B
$1.53B
$1.41B
$1.39B
Cost of revenue
$369.2M
$392.4M
$362.6M
$343M
$345.2M
$344.4M
$301.6M
$292.2M
Gross profit
$1.35B
$1.35B
$1.29B
$1.23B
$1.21B
$1.19B
$1.11B
$1.09B
Selling, general and administrative
$560.9M
$561.2M
$522.2M
$602.9M
$514.6M
$502M
$465.7M
$491.9M
Research and development
$281.4M
$278.9M
$263.3M
$267.7M
$280.7M
$276.2M
$254.6M
$271.1M
Total operating expenses
$1.05B
$835.4M
$808.4M
$1.13B
$913.3M
$776.6M
$716.3M
$803.7M
Operating income
$299.1M
$513.2M
$477.6M
$96.8M
$294.6M
$411.2M
$394.8M
$289.9M
Interest expense
$0
$30M
$0
-$20.4M
$0
$37.4M
$0
-$19.8M
Income before taxes
$363.2M
$519.8M
$459M
$90.4M
$348.4M
$400.2M
$433.9M
$390.1M
Income taxes
$61.8M
$278.4M
$78.3M
$26.2M
$56.1M
$64.3M
$70.3M
$45.1M
Net income
$301.4M
$241.4M
$380.7M
$91.2M
$290.3M
$331.5M
$363.6M
$384.3M
Net income attributable to common shareholders
$307.5M
$241.9M
$380.7M
$91.2M
$291.1M
$333.2M
$358M
$385.6M
EBITDA
$562.2M
$562.2M
$555.6M
$398.7M
$464.3M
$469M
$446.5M
$373.2M
Basic earnings per share
$0.53
$0.42
$0.66
$0.16
$0.50
$0.57
$0.61
$0.65
Diluted earnings per share
$0.53
$0.42
$0.66
$0.16
$0.50
$0.56
$0.61
$0.65
Recent news
Company coverage with links to the original publishers.
Boston Scientific (BSX) lowered its 2026 sales growth forecast to 4.25% and adjusted EPS guidance to $3.16-$3.18 due to unexpected headwinds in its WATCHMAN and Electrophysiology franchises. WATCHMAN organic sales fell 5.9% amid weakening demand, while Electrophysiology declined 5.3% due to competitive pressure from Pulsed Field Ablation technologies. The company faces additional challenges from delayed product launches, elevated debt levels, and a cybersecurity incident that accelerated competitive share losses. BSX shares have declined 53.5% year-to-date, significantly underperforming peers and the broader market.
Zacks analysts published research on 16 major stocks on November 13, 2026. Visa benefits from strong brand and digital growth but faces profitability pressures. ExxonMobil gains from low-cost production and expansion opportunities but faces commodity volatility risks. Pfizer underperforms peers due to patent expirations and subdued growth, though pipeline investments offer longer-term potential. Additional coverage includes U.S. Bancorp, Blackstone, Edwards Lifesciences, and others with mixed outlooks.
Boston Scientific's WATCHMAN left atrial appendage closure device continues to face declining demand despite positive clinical trial results and expansion efforts. The company expects low-single-digit sequential sales declines in Q3 2026 and assumes no market improvement in 2027, while competitors like Abbott and Edwards Lifesciences show stronger momentum in electrophysiology and structural heart segments.
The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.
Intuitive Surgical reported a 28% year-over-year increase in da Vinci system placements to 546 units in Q3 2026, with systems revenues rising 30% to $769M. The growth was driven by multisystem orders, hospital capacity expansions, and upgrades to the da Vinci 5 platform. Recurring revenues represented 84% of Q3 sales, reflecting strong system utilization. However, the article notes that capital spending remains uneven and sustained acceleration will depend on continued healthy capital spending and higher procedure volumes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.